Insmed Company Profile

09:07 EST 18th November 2017 | BioPortfolio

Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with metabolic diseases that currently have limited treatment options. The company’s lead product, IPLEXTM, approved by the FDA in December 2005, is a composition of recombinant human IGF-1 and IGFbinding protein 3. IPLEXTM is now being studied as a treatment for several serious medical conditions, including two neuromuscular disorders, Myotonic Muscular Dystrophy (MMD) and ALS (Lou Gehrig’s Disease); HIV- Associated Adipose Redistribution Syndrome (HARS); and retinopathy of prematurity (ROP). Cumulatively, these disorders affect more than 100,000 patients in the United States, and an equal number in the European Union. Insmed is also developing novel products for the treatment of cancer. INSM-18 and rhIGFBP-3 are promising potential novel treatments for a variety of cancer types. Preclinical models demonstrate that both treatments interact with the IGF system to reduce tumor growth. Headquartered in Richmond, Virginia, Insmed maintains a state-of the-art FDA-approved biologic commercial manufacturing facility, Insmed Therapeutic Proteins, in Boulder, Colorado.


8720 Stony Point Parkway
Suite 200
United States of America


Phone: 804-565-3000
Fax: 804-565-3500

News Articles [39 Associated News Articles listed on BioPortfolio]

Insmed, Inc. (INSM) Expected to Post Earnings of -$0.63 Per Share

Brokerages expect Insmed, Inc. to report earnings of per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Insmed's earnings.

Insmed in the money as lung disease study comes good

The share value of US rare diseases specialist Insmed more than doubled on Tuesday based on the top-line…

ALIS In Wonderland: Insmed Reaches Fairy Tale Heights On Lung Disease Results

Insmed will commercialize ALIS, its inhaled amikaycin formerly known as Arikayce, on its own for a rare, bacteria-driven lung disease...   

STAT Plus: Insmed inhaled antibiotic clears rare lung disease in pivotal study

An inhaled antibiotic from Insmed (INSM) successfully treated patients with a rare lung disease caused by a bacterial infection, according to results from a phase 3 clinical trial reported Tuesday....

Insmed shares skyrocket after lung drug meets key study's main goal

(Reuters) - Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accele...

Insmed Phase III Date Support Accelerated Approval For ALIS In Rare Lung Disease

Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in...    

Insmed's lung drug meets main goal in key study, shares soar

Insmed Inc said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading on Tuesday. The drug, Alis, was used for the treatm...

Insmed nets $329mm via FOPO

Respiratory disease-focused Insmed Inc. netted $329mm through a follow-on public offering of 12.28mm common shares priced at $28.50 each. The company will use the funds for ongoing clinical trials of ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

The aim of this study is to investigate the safety and feasibility of daily subcutaneous injections of recombinant IGF1 complexed with IGF binding protein 3 (SomatoKine-INSMED) as a treatm...

Companies [3 Associated Companies listed on BioPortfolio]

Insmed Inc.

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please ...

Insmed Incorporated

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercial...


Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with metabolic diseases that currently have limited treatm...

More Information about "Insmed" on BioPortfolio

We have published hundreds of Insmed news stories on BioPortfolio along with dozens of Insmed Clinical Trials and PubMed Articles about Insmed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Insmed Companies in our database. You can also find out about relevant Insmed Drugs and Medications on this site too.

Quick Search

Relevant Topic

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Corporate Database Quicklinks

Searches Linking to this Company Record